Ruley E J, Bock G H, Smith D
J Pediatr. 1982 Dec;101(6):1013-7. doi: 10.1016/s0022-3476(82)80035-8.
Saralasin acetate, a competitive inhibitor of angiotensin II, was administered as a continuous infusion to two pediatric patients for 8 and 13 days, respectively, to control hypertension. Both patients had become refractory to parenterally administered antihypertensive medications and had an ileus that precluded drug treatment orally. Both patients had a reduction in blood pressure of 30% in response to intravenous infusion of saralasin as a diagnostic test. In the patient with renal failure, neither saralasin nor ultrafiltration was effective alone, but blood pressure was controlled when their use was combined. In these two patients the continuous infusion of saralasin proved to be an effective means for blood pressure control and was unassociated with any recognized adverse effects.
醋酸沙拉新，一种血管紧张素II的竞争性抑制剂，分别对两名儿科患者进行了8天和13天的持续输注以控制高血压。两名患者对胃肠外给予的抗高血压药物均已产生耐药性，且患有肠梗阻，无法口服药物治疗。作为诊断试验，静脉输注沙拉新后，两名患者的血压均降低了30%。在肾衰竭患者中，单独使用沙拉新或超滤均无效，但联合使用时血压得到了控制。在这两名患者中，持续输注沙拉新被证明是控制血压的有效手段，且未出现任何公认的不良反应。
